Amniotics

Amniotics develops and manufactures stem cell therapies in our own GMP certified facility. Amniotics was born out of the discovery of a novel source of stem cells in full-term amniotic fluid. Amniotics completed and process validated a GMP manufacturing facility at our premises in Medicon Village in Lund, Sweden in 2020. We are offering contract development and contract manufacturing of Advanced therapy medicinal product (ATMPs) to the pharmaceutical industry, to Universities and to hospitals. Amniotics is now in clinical phase with the leading drug candidate PulmoStem™ targeting severe lung diseases and is looking to establish strategic partnerships with researchers and companies that are interested in developing stem-cell-based therapies targeting diseases with high unmet needs. We are devoted to developing innovative life-changing and regenerative treatments for patients. In addition Amniotics work as a CDMO, providing GMP manufacture of ATMPs (Advanced Therapy Medicinal Products) to universities, hospitals, and the biopharmaceutical industry. At Amniotics™, we aim to positively impact the lives of patients and their families with severe diseases by developing innovative therapies.